Article Text

Download PDFPDF
NICE recommendations for the management of hyperglycaemia in acute coronary syndrome
  1. Simon J Corbett
  1. Correspondence to Dr Simon Corbett, Consultant Cardiologist, University Hospital Southampton NHS Foundation Trust, member of the Guideline Development Group for NICE CG 130, Wessex Cardiothoracic Centre, Tremona Road, Southampton SO16 6YD, UK; scorbett{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


It is well established that hyperglycaemia is common in patients admitted to the hospital with acute coronary syndrome (ACS), and is an an independent risk factor for adverse outcome.1 ,2 A significant proportion of these patients with ACS and hyperglycaemia will not previously have been diagnosed with diabetes mellitus, and not all of them will automatically turn out to be diabetic in the long term.2 It is therefore unsurprising that a number of studies have tried to evaluate the best way to manage hyperglycaemia in ACS.3–6 However, the results have been mixed, contradictory on occasion, and even identified for potential for harm. The waters are muddied further by significant heterogeneity between studies across important factors, such as: the patient populations studied (eg, hyperglycaemic ACS patients,3 versus intensive insulin therapy in unselected ACS patients with or without hyperglycaemia6); and the nature and efficacy of intensive insulin therapy under evaluation (eg, the patients treated with an intensive insulin regimen in DIGAMI-2 did not achieve as good a glycaemic control as intended4). There is a correspondingly wide variation in practice, and it is for this reason that NICE was asked to evaluate the evidence and produce a clinical guideline to guide contemporary practice in this area in England and Wales.7


The guideline was produced in accordance with NICE's short clinical guideline process using the methodology set out in the NICE Guideline Manual (2009).8 For those without experience of developing NICE guidance, a brief review of this process may help in understanding not only how NICE produces its recommendations, but also why they are drafted the way they are, particularly if the guidance may be considered controversial. The guideline topic is referred to NICE by the Department of Health. National organisations representing patients and carers, …

View Full Text


  • Linked article 301975.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles